Cowen and Company’s Edgewise Therapeutics EWTX Stock Holding History

Cowen and Company’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,000	Closed	-$294K	–	120
2024 Q3	$294K	Buy	+11,000	New	+$219K	0.01%	208

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Cowen and Company's EWTX Position: Q4 2024 in Review

Cowen and Company sold out of Edgewise Therapeutics (EWTX) in Q4 2024, closing a stake of 11,000 shares — an estimated $294K sold.

Cowen and Company first reported a position in EWTX in Q3 2024 and held it in 1 quarter. The position peaked at $294K in Q3 2024. 200 funds tracked by Wall St. Rank hold EWTX as of Q4 2024.

Cowen and Company reported no remaining Edgewise Therapeutics position as of Q4 2024 after selling out during the quarter.
Cowen and Company sold 11,000 Edgewise Therapeutics shares in Q4 2024, an estimated $294K.
Cowen and Company first reported a position in Edgewise Therapeutics in Q3 2024 and held it in 1 quarter.
Cowen and Company's Edgewise Therapeutics position peaked at $294K in Q3 2024.
200 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.